# OnCo record paper-monumental-1-talquetamab-nejm-2022 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-monumental-1-talquetamab-nejm-2022/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-monumental-1-talquetamab-nejm-2022" ;
  schema:name "MonumenTAL-1: talquetamab, a GPRC5D-directed bispecific antibody for relapsed multiple myeloma"@en ;
  schema:description "Talquetamab, an antibody that pulls T cells onto a new myeloma target called GPRC5D, produced responses in about seven in ten heavily pretreated patients, including those already treated with BCMA-directed therapy."@en ;
  schema:url <https://onco.cc/key-papers/paper-monumental-1-talquetamab-nejm-2022/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://doi.org/10.1056/NEJMoa2204591>, <https://pubmed.ncbi.nlm.nih.gov/36507686/> ;
  schema:sameAs <https://doi.org/10.1056/NEJMoa2204591> ;
  schema:datePublished "2022"^^xsd:gYear ;
  schema:author "Chari A, Minnema MC, Berdeja JG, et al." ;
  onco:cancers <https://onco.cc/cancers/myeloma-relapsed-refractory/> ;
  onco:drugs <https://onco.cc/drugs/mcla-129/>, <https://onco.cc/drugs/talquetamab/> ;
  onco:trials <https://onco.cc/trials/monumental-1/> ;
  onco:journals <https://onco.cc/journals/nejm/> .